Abstract | BACKGROUND: OBJECTIVE: We sought to evaluate adalimumab's efficacy in treating GA. METHODS: We identified 7 patients with physician-verified GA who were treated with adalimumab. Primary endpoints were improvements in GA Investigator Global Assessment score and body surface area. Secondary end points included erythema and induration improvement. RESULTS: Seven adults, ages 51 to 77 years, were included. All patients' GA Investigator Global Assessment scores improved by 2 or greater. We found significant improvements in body surface area, erythema, and induration (average improvements by 87%, 88%, and 95%, respectively). Two patients required increases in adalimumab frequency. Two others noted GA recurrence; 1 restarted adalimumab and cleared again. Adverse events were minimal. LIMITATIONS: Conclusions are limited because of small sample size and observational nature of the study. CONCLUSION: Our results suggest that adalimumab could be an effective and well-tolerated treatment for GA. It is a particularly attractive therapy for patients who have generalized or disseminated GA.
|
Authors | Michelle S Min, Mark Lebwohl |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 74
Issue 1
Pg. 127-33
(Jan 2016)
ISSN: 1097-6787 [Electronic] United States |
PMID | 26552891
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Tumor Necrosis Factor-alpha
- Adalimumab
|
Topics |
- Adalimumab
(therapeutic use)
- Aged
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Granuloma Annulare
(drug therapy, pathology)
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Sampling Studies
- Severity of Illness Index
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(administration & dosage, antagonists & inhibitors)
|